Correction to: Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. [PDF]
Oncologisteuropepmc +2 more sources
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in <i>RET</i> fusion-positive non-small cell lung cancer. [PDF]
Future OncolHochmair M +7 more
europepmc +1 more source
Real-world clinical responses to selpercatinib in RET M918T-mutant medullary thyroid carcinoma. [PDF]
Discov OncolÖkten IN, Baydaş T.
europepmc +1 more source
An Uncommon Presentation of Selpercatinib (Retevmo)-Induced Severe Transaminitis: A Biopsy-Proven Case Report. [PDF]
CureusBiswas N, Dudhia K.
europepmc +1 more source
Preoperative selpercatinib induces major pathological response in a patient with stage IIIA, RET fusion-positive non-small cell lung cancer: A case report. [PDF]
Medicine (Baltimore)Breitenecker K +7 more
europepmc +1 more source
Durable Response to Selpercatinib in Metastatic Colorectal Cancer Harboring a Novel <i>TIMM23B::RET</i> Fusion: A Case Report. [PDF]
Curr OncolTong Z, Yang M, Weng S, Yuan Y.
europepmc +1 more source
Treatment of non-small cell lung cancer with RET rearrangements. [PDF]
CancerHoe HJ, Solomon BJ.
europepmc +1 more source
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. [PDF]
J Clin OncolGautschi O +12 more
europepmc +1 more source
Selpercatinib in Chinese patients with <i>RET</i>-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial. [PDF]
Ther Adv Med OncolLu S +9 more
europepmc +1 more source
Selpercatinib for RET fusion-positive non-small cell lung cancer. [PDF]
Aust Prescreuropepmc +1 more source